CUE Cue Biopharma, Inc.: institutional ownership and insider trading
51 funds reported holding $52.5M of Cue Biopharma, Inc. in their latest 13F filings; in Q2 2026 funds net bought $53.6M, with 50 new positions and 1 funds selling out; over the last 12 months insiders bought $99.7K and sold $2.43M on the open market.
Famous investors holding CUE
- Ken Griffin (Citadel Advisors): $809K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $464K, 0.0% of the portfolio
Largest institutional holders of CUE
- Bleichroeder LP — $11.7M
- DRIEHAUS CAPITAL MANAGEMENT LLC — $9.22M
- VANGUARD CAPITAL MANAGEMENT LLC — $5.10M
- Ikarian Capital, LLC — $3.29M
- TFG Asset Management GP Ltd — $2.96M
- STEMPOINT CAPITAL LP — $2.11M
- BlackRock, Inc. (BLK) — $1.82M
- ADAR1 Capital Management, LLC — $1.74M
- Lion Point Capital, LP — $1.67M
- Squadron Capital Management LLC — $1.58M
Recent CUE insider trades
- Oct 12, 2026: Ray Sumita sold 1,844 shares ($51.7K)
- Oct 12, 2026: Lin Shao-Lee sold 11,087 shares ($305K)
- Oct 12, 2026: Meluzio Michael Vincent sold 1,144 shares ($32.1K)
- Aug 13, 2026: Ray Sumita sold 8,829 shares ($266K)
5%+ owners
- Mark E. Strome: 8.5% (Schedule 13G/A, filed Oct 8, 2026)
- DRIEHAUS CAPITAL MANAGEMENT LLC: 7.0% (Schedule 13G, filed Aug 14, 2026)
- Shao-Lee Lin: 6.2% (Schedule 13D, filed Aug 21, 2026)